CNBX — CNBX Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $0.18m
- $1.43m
- $0.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -131.96% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | 0.01 | n/a | n/a | 0.41 | n/a | n/a | 111.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Directors
- Gabriel Yariv CHM (44)
- Eyal Barad CEO (56)
- Uri Ben-Or CFO (51)
- Eyal Ballan CTO (48)
- Gil Feiler IND (62)
- Inbar Maymon - Pomeranchik IND (44)
- Shaul Yemal IND (73)
- Last Annual
- August 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- September 15th, 2004
- Public Since
- July 2nd, 2007
- No. of Shareholders
- 57
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 31,111,352
- Address
- #3 Bethesda Metro Center, Suite 700, BETHESDA, 20814
- Web
- https://cnbxpharma.com/
- Phone
- +1 8774242429
- Auditors
- Weinstein International CPA
Upcoming Events for CNBX
Q4 2024 CNBX Pharmaceuticals Inc Earnings Release
Similar to CNBX
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the CNBX Pharmaceuticals share price?
As of Today at 20:01 UTC, shares in CNBX Pharmaceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
How has the CNBX Pharmaceuticals share price performed this year?
Shares in CNBX Pharmaceuticals last closed at $0.01 and the price had moved by -44.06% over the past 365 days. In terms of relative price strength the CNBX Pharmaceuticals share price has underperformed the S&P500 Index by -53.05% over the past year.
What are the analyst and broker recommendations for CNBX Pharmaceuticals?
There is no consensus recommendation for this security.
What is the CNBX Pharmaceuticals dividend yield?
CNBX Pharmaceuticals does not currently pay a dividend.
Does CNBX Pharmaceuticals pay a dividend?
CNBX Pharmaceuticals does not currently pay a dividend.
When does CNBX Pharmaceuticals next pay dividends?
CNBX Pharmaceuticals does not currently pay a dividend.
How do I buy CNBX Pharmaceuticals shares?
To buy shares in CNBX Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CNBX Pharmaceuticals?
As of the previous close price of $0.01, shares in CNBX Pharmaceuticals had a market capitalisation of $0.25m.
Where are CNBX Pharmaceuticals shares listed?
Here are the trading details for CNBX Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CNBX
What kind of share is CNBX Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum CNBX Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CNBX Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the CNBX Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CNBX Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -39.63%.
As of the last closing price of $0.01, shares in CNBX Pharmaceuticals were trading -43.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CNBX Pharmaceuticals PE Ratio?
The CNBX Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CNBX Pharmaceuticals?
CNBX Pharmaceuticals' management team is headed by:
- Gabriel Yariv - CHM
- Eyal Barad - CEO
- Uri Ben-Or - CFO
- Eyal Ballan - CTO
- Gil Feiler - IND
- Inbar Maymon - Pomeranchik - IND
- Shaul Yemal - IND